Parallel trade, price discrimination, investment and price caps

Economic Policy

Volumn 20, Issue 44, 2005, Pages 705-749

  Szymanski, Stefan ^a   Valletti, Tommaso ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CEPR ^*

Author keywords

[No Author keywords available]

Indexed keywords

INVESTMENT; MARKET SYSTEM; PRICE DYNAMICS; TRADE; WELFARE IMPACT;

EID: 33747754884     PISSN: 02664658     EISSN: 14680327     Source Type: Journal    
DOI: 10.1111/j.1468-0327.2005.00149.x     Document Type: Conference Paper

References (33)

1. Abbott, F.M. (1998). 'First report (final) to the Committee on International Trade Law of the International Law Association on the subject of parallel importation', Journal of International Economic Law, 1 (4), 607-36.
2. Ahmadi, R. and B. Yang (2000). 'Parallel imports: Challenges from unauthorized distribution channels', Marketing Science, 19 (3), 279-94.
3. Anderson, S. and V. Ginsburgh (1999). 'International pricing with costly consumer arbitrage', Review of International Economics, 7 (1), 126-39.
4. Bordoy, C. and I. Jelovac (2005). 'Pricing and welfare implications of parallel imports in the pharmaceutical industry', International Journal of Health Care Finance and Economics, 5(1), 5-21.
5. Commission on Intellectual Property Rights (2002). Integrating Intellectual Property Rights and Development Policy. London.
6. Crampes, C. and A. Hollander (2003). 'The pricing of pharmaceuticals facing parallel imports', mimeo, IDEI, University of Toulouse.
7. Danzon P. (1997). 'Price discrimination for pharmaceuticals: Welfare effects in the US and the EU', International Journal of the Economics of Business, 4 (3), 301-21.
8. Danzon, P. (1998). 'The economics of parallel trade', Pharmacoeconomics, 13 (3), 293-304.
9. Danzon, P. and A. Towse (2003). 'Differential pricing for pharmaceuticals: Reconciling access, R&D and patents', International Journal of Health Care Finance and Economics, 3, 185-205.
10. Gallini, N. and A. Hollis (1999). 'A contractual approach to the Gray Market', International Review of Law and Economics, 19, 1-21.
11. Ganslandt, M. and K.E. Maskus (2004). 'The price impact of parallel imports in pharmaceuticals: Evidence from the European Union', Journal of Health Economics, 23, 1035-57.
12. Graham, J. and B. Robson (2000). 'Prescription drug pricing in Canada and the United States -Part 1: A comparative survey', Public Policy Sources 42, Vancouver (BC), The Fraser Institute.
13. Hausman, J.A. and J.K. MacKie-Mason (1988). 'Price discrimination and patent policy', RAND Journal of Economics, 19 (2), 253 -65.
14. Johnson, J.P. and D.P. Myatt (2003). 'Multiproduct quality competition: Fighting brands and product line pruning', American Economic Review, 93, 748-74.
15. Kanavos, P., J. Costa-I-Font, S. Merkur and M. Gemill (2004). 'The economic impact of pharmaceutical parallel trade in European Union member states: A stakeholder analysis', Special Research Paper, LSE Health and Social Care.
16. Li, C. and K.E. Maskus (2004). 'Parallel imports and cost-reducing research and development', Journal of International Economics, forthcoming.
17. Malueg, D. and M. Schwartz (1994). 'Parallel imports, demand dispersion and international price discrimination', Journal of International Economics, 37, 167-95.
18. Maskus, K. and Y. Chen (2004). 'Vertical price control and parallel imports: Theory and evidence', Review of International Economics, 12(4), 551-70.
19. Mussa, M. and S. Rosen (1978). 'Monopoly and product quality', Journal of Economic Theory, 18, 301-17.
20. National Economic Research Associates (NERA) (1999). 'The economic consequences of the choice of a regime of exhaustion in the area of trademarks', Final Report for DGXV of the European Commission. 1999
21. New Zealand Institute of Economic Research (NZIER) (1999). 'Parallel importing: A theoretical and empirical investigation', Report to Ministry of Commerce.
22. OECD (2002). Synthesis Report on Parallel Imports, OECD, Paris.
23. Pecorino, P. (2002). 'Should the US allow prescription drug reimports from Canada?' Journal of Health Economics, 21, 699-708.
24. Rey, P. (2003) The impact of parallel imports on prescription medicines, mimeo, IDEI, University of Toulouse.
25. Rey, P. and J. Stiglitz (1995). 'The role of exclusive territories in producers'competition' Rand Journal of Economics, 26(3), 431-51.
26. Richardson, M. (2002). 'An elementary proposition concerning parallel imports', Journal of International Economics, 56, 233-45.
27. Swedish Competition Authority (1999). Parallel Imports - Effects of the Silhouette Ruling, Swedish Competition Authority, Report Series 1999:1.
28. Sykes, A. (2002). TRIPs, pharmaceuticals, developing countries, and the Doha "Solution", University of Chicago Law and Economics, Olin Working Paper No. 140.
29. Tarr, D.G. (1985). An economic analysis of grey market imports', mimeo, US Federal Trade Commission, Washington, DC.
30. Valletti, T. (2004). 'Differential pricing, parallel trade, and incentives to invest', Journal of International Economics, forthcoming.
31. Valletti, T. and S. Szymanski (2004). 'Parallel trade, international exhaustion and intellectual property rights: A welfare analysis', Journal of Industrial Economics, forthcoming.
32. Varian, H. (1985). 'Price discrimination and social welfare', American Economic Review, 75, 870-75.
33. West J. and P. Mahon (2003). Benefits to Payers and Patients from Parallel Trade, York Health Economics Consortium, University of York.